WMT for Recurrent Urinary Tract Infections
NCT07627412
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Nanjing, Jiangsu, China
View Trial DetailsNCT Number: NCT02641015
A retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant gram-negative bacteria (COMBACTE-MAGNET,WP5)
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Emergency Hospital Pirogov, Sofia, Bulgaria
Bacterial resistance to antimicrobial drugs is a major public health problem. Of greatest concern is the rapid emergence and dissemination of resistance to third generation cephalosporins in Enterobacteriaceae, especially Escherichia coli and Klebsiella pneumoniae. This is frequently seen in association with resistance to other classes of antibiotics leading to a multidrug resistance (MDR) profile. These MDR isolates are often involved in complicated urinary tract infection (cUTI), and are associated with poor clinical outcomes. In addition, in the last decade there has been an emergence of carbapenemase-producing Enterobacteriaceae, which are also resistant to other antibiotics than carbapenems, leaving few therapeutic options.
The overall aim of this study is to provide information about the epidemiology, clinical management and outcome of patients hospitalised with cUTI, including pyelonephritis. To achieve this aim, the investigators will perform a multicentre retrospective observational study in patients with hospitalised cUTI. The study will be conducted in several European countries plus Israel, which have a high prevalence of MDR Gram-negative bacteria (GNB), including Pseudomonas aeruginosa. The study will seek to identify possible modifiable risk factors for treatment failure, especially those related to antibiotic therapy.
On completion of this study, the investigators will develop a better understanding of the clinical management of hospitalised patients with cUTI due to MDR GNB in European countries. The investigators will identify the modifiable risk factors for treatment failure. This information will be used to inform better clinical and antibiotic management of cUTI to improve patient outcomes. The study will also be used in the development of hypothesis for future randomised controlled trials in cUTI with new antibiotics. Dissemination of results will take place through peer-reviewed publications and conference presentations.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients with UTI and at least one of the following underlying conditions:
and at least one of the following signs or symptoms:
and at least one of the following microbiological results:
Exclusion criteria
Time frame: 30 days
Treatment failure will be assessed as number of participants with evidence of treatment failure or mortality within 30 days from initial cUTI diagnosis
Time frame: 30 days
Time to clinical response (in days), since initiation of antibiotic treatment
Time frame: 30 days
Time to urological intervention for source control (in days) since initial cUTI diagnosis
Time frame: 30 days
Time to death (in days) since original cUTI diagnosis
Time frame: 30 days
Duration of antibiotic therapy (in days)
Time frame: 30 days
Length of hospital stay (in days)
Time frame: 30 days
Hospital mortality during admission
Time frame: 30 days
All cause mortality within 30 days of the original cUTI diagnosis
Time frame: 60 days
All cause of mortality for two months after hospital discharge
Time frame: 30 days
Cost per case of cUTI
Time frame: 60 days
Readmissions to the hospital within 60 days of hospital discharge
Time frame: 30 days
Adverse events related to antibiotic treatment including: moderate or severe allergic reactions, severe renal impairment, Clostridium difficile infection
Institut d'Investigació Biomèdica de Bellvitge
Other
A Retrospective Observational Study to Assess the Clinical Management and Outcomes of Hospitalised Patients With Complicated Urinary Tract Infection in Countries With High Prevalence of Multidrug Resistant Gram-negative Bacteria.
Acronym: RESCUING
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07627412
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Nanjing, Jiangsu, China
View Trial DetailsNCT06801405
Acute Kidney Injury, Antibiotic Prophylaxis
Jales, São Paulo, Brazil
View Trial DetailsNCT05319561
Common Infections, Female Urogenital Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT07438184
Chronic Prostatitis (CP), Female Urogenital Diseases
Salamanca, Spain
View Trial Details